Investing21d
Ascendis Pharma’s SWOT analysis: stock outlook amid Yorvipath success, Skytrofa challenges
The potential upside from other products like Yorvipath and TransCon CNP is seen as a counterbalance to Skytrofa’s current underperformance. Ascendis Pharma’s pipeline includes TransCon CNP, a ...
Investing21d
Ascendis Pharma's SWOT analysis: stock outlook amid Yorvipath success, Skytrofa challenges
The potential upside from other products like Yorvipath and TransCon CNP is seen as a counterbalance to Skytrofa's current underperformance. Ascendis Pharma's pipeline includes TransCon CNP ...
Investing22d
BioMarin's SWOT analysis: rare disease leader's stock faces growth and competition challenges
Despite potential competition from products like TransCon CNP and infigratinib, Voxzogo's unique positioning and strong commercial capabilities are expected to protect its market share. Roctavian, ...
Morningstar28d
BioMarin Earnings: Sales Driven by Strong Uptake of Voxzogo and Enzyme Therapies; Shares Undervalued
as it could face competition in the future from BridgeBio’s infigratinib and Ascendis Pharma’s TransCon CNP. We forecast BioMarin will achieve 2025 revenue of $3.17 billion, growing 11% ...
Yahoo Finance19d
Ascendis Pharma A/S (ASND)
“This marks another step toward – YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 – TransCon CNP NDA ...
Hosted on MSN15d
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing
Ascendis also confirmed plans to submit regulatory filings for TransCon CNP as a treatment for children with achondroplasia. The board also authorized up to $18.25 million for repurchases of its ...